Market Cap 50.99M
Revenue (ttm) 190,000.00
Net Income (ttm) -74.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -39,010.53%
Debt to Equity Ratio 0.00
Volume 1,463,637
Avg Vol 2,385,916
Day's Range N/A - N/A
Shares Out 98.05M
Stochastic %K 78%
Beta 0.55
Analysts Sell
Price Target $2.75

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 731 8389
Fax: 858 731 8394
Address:
10240 Sorrento Valley Road, Suite 300, San Diego, United States
__Godzilla__
__Godzilla__ Jun. 4 at 8:45 PM
$ATYR Conference Presentation Highlights from today: Met with FDA Another phase 3 trial is required New study will use forced vital capacity (FVC) at week 48 as primary endpoint with 372 study population Expect to get the trial protocol to the FDA this month Trial will start later this year 17 doses instead of 12 Study population will be those of a restrictive lung phenotype, which is a 40,000 patient opportunity instead of 90,000, but the treatment will probably be priced higher New study will not need steroid taper They have not figured out the capital raise yet, but they want to advance to program in the most capital efficient manner
0 · Reply
Landon167
Landon167 Jun. 4 at 8:44 PM
$ATYR 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers aTyr Pharma (NASDAQ:ATYR) shares rose 21.0% to $0.59 during Thursday's after-market session. The market value of their outstanding shares is at $46.8 million.
0 · Reply
Indialli1309
Indialli1309 Jun. 4 at 8:19 PM
$ATYR Fantastic presentation today. One of the obstacles with Atyr is that the company aims to better the life of people who are very sick. So the mechanism behind the drug are quite difficult to understand. But this company are pioneers in their field and this drug will help hundreds of thousands of people in coming years! Buy the stock and you will reap in coming months and years.
0 · Reply
Cheffinance
Cheffinance Jun. 4 at 7:26 PM
$ATYR bad signs...
3 · Reply
Indialli1309
Indialli1309 Jun. 4 at 3:46 PM
$ATYR Very interesting!💪
0 · Reply
X600X
X600X Jun. 4 at 2:23 PM
0 · Reply
X600X
X600X Jun. 4 at 2:23 PM
$ATYR Gooooooo $ATYR
0 · Reply
Cheffinance
Cheffinance Jun. 4 at 1:42 PM
$ATYR I don't like this kind of decision about 8k. What they want to do now? This is very strange...something is cooking but I don't understand if it's something good or bad...
1 · Reply
DeexNutzz
DeexNutzz Jun. 4 at 2:09 AM
$ATYR The 180 day extension is in the bag the June 2nd deadline passed with no effect but I don’t much expect a big move from the extension. The fireside chat and the new phase 3 Ind may post a moderate bump but above $1 on that alone I bot site about. Good phase 2 EFZOFIT news will bring a big move and the rub up to that announcement will ensure our compliance. That will also be a good time for an offering to raise money but keep us above $1 per share. Keep in mind EFZOFITOMOD is worth 2 billion if it goes to markwt and their product currently in phase 2 is worth 5 billion if it goes to market! YUM! This is a long term play and I am using crypto play leverage money for it and with crypto tanking and going into crypto winter it is better to keep it here until thing thaw and I may make money to boot!
0 · Reply
X600X
X600X Jun. 3 at 10:57 PM
$ATYR $RDW $SLS $SPIR Dear Short's the Snake just waiting for your Action , don't Short and just go Home.
0 · Reply
Latest News on ATYR
aTyr Pharma upgraded to Buy from Hold at Freedom Broker

2026-05-20T13:00:12.000Z - 15 days ago

aTyr Pharma upgraded to Buy from Hold at Freedom Broker


Ethos to Present at Upcoming Investor Conferences

May 15, 2026, 4:30 PM EDT - 20 days ago

Ethos to Present at Upcoming Investor Conferences

LIFE


aTyr Pharma reports Q1 EPS (11c), consensus (15c)

2026-05-15T15:42:31.000Z - 20 days ago

aTyr Pharma reports Q1 EPS (11c), consensus (15c)


aTyr Pharma Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 20 days ago

aTyr Pharma Quarterly report: Q1 2026


aTyr Pharma Earnings release: Q1 2026

May 15, 2026, 7:00 AM EDT - 20 days ago

aTyr Pharma Earnings release: Q1 2026


Ethos Announces Early Lock-Up Release

May 13, 2026, 4:35 PM EDT - 22 days ago

Ethos Announces Early Lock-Up Release

LIFE


aTyr Pharma to Participate in Upcoming Investor Conferences

May 13, 2026, 4:01 PM EDT - 22 days ago

aTyr Pharma to Participate in Upcoming Investor Conferences


aTyr Pharma Transcript: Study update

May 11, 2026, 4:30 PM EDT - 24 days ago

aTyr Pharma Transcript: Study update


aTyr Pharma Press release: Study update

May 11, 2026, 4:30 PM EDT - 24 days ago

aTyr Pharma Press release: Study update


aTyr Pharma Slides: Study update

May 11, 2026, 4:30 PM EDT - 24 days ago

aTyr Pharma Slides: Study update


aTyr Pharma Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 2 months ago

aTyr Pharma Proxy statement: Proxy filing


aTyr Pharma Proxy statement: Proxy filing

Mar 26, 2026, 8:00 AM EDT - 2 months ago

aTyr Pharma Proxy statement: Proxy filing


aTyr Pharma Proxy statement: Proxy Filing

Mar 12, 2026, 8:00 AM EDT - 3 months ago

aTyr Pharma Proxy statement: Proxy Filing


aTyr Pharma reports Q4 EPS (14c), consensus (17c)

2026-03-05T21:05:56.000Z - 3 months ago

aTyr Pharma reports Q4 EPS (14c), consensus (17c)


aTyr Pharma Annual report: Q4 2025

Mar 5, 2026, 3:00 PM EST - 3 months ago

aTyr Pharma Annual report: Q4 2025


aTyr Pharma Earnings release: Q4 2025

Mar 5, 2026, 3:00 PM EST - 3 months ago

aTyr Pharma Earnings release: Q4 2025


Ethos to Participate in The Citizens Technology Conference

Feb 26, 2026, 4:06 PM EST - 3 months ago

Ethos to Participate in The Citizens Technology Conference

LIFE


Ethos Announces Pricing of Initial Public Offering

Jan 28, 2026, 10:38 PM EST - 4 months ago

Ethos Announces Pricing of Initial Public Offering


aTyr Pharma reports Q3 EPS (26c), consensus (18c)

2025-11-06T21:26:32.000Z - 7 months ago

aTyr Pharma reports Q3 EPS (26c), consensus (18c)


aTyr Pharma Earnings release: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

aTyr Pharma Earnings release: Q3 2025


aTyr Pharma Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 7 months ago

aTyr Pharma Quarterly report: Q3 2025


__Godzilla__
__Godzilla__ Jun. 4 at 8:45 PM
$ATYR Conference Presentation Highlights from today: Met with FDA Another phase 3 trial is required New study will use forced vital capacity (FVC) at week 48 as primary endpoint with 372 study population Expect to get the trial protocol to the FDA this month Trial will start later this year 17 doses instead of 12 Study population will be those of a restrictive lung phenotype, which is a 40,000 patient opportunity instead of 90,000, but the treatment will probably be priced higher New study will not need steroid taper They have not figured out the capital raise yet, but they want to advance to program in the most capital efficient manner
0 · Reply
Landon167
Landon167 Jun. 4 at 8:44 PM
$ATYR 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers aTyr Pharma (NASDAQ:ATYR) shares rose 21.0% to $0.59 during Thursday's after-market session. The market value of their outstanding shares is at $46.8 million.
0 · Reply
Indialli1309
Indialli1309 Jun. 4 at 8:19 PM
$ATYR Fantastic presentation today. One of the obstacles with Atyr is that the company aims to better the life of people who are very sick. So the mechanism behind the drug are quite difficult to understand. But this company are pioneers in their field and this drug will help hundreds of thousands of people in coming years! Buy the stock and you will reap in coming months and years.
0 · Reply
Cheffinance
Cheffinance Jun. 4 at 7:26 PM
$ATYR bad signs...
3 · Reply
Indialli1309
Indialli1309 Jun. 4 at 3:46 PM
$ATYR Very interesting!💪
0 · Reply
X600X
X600X Jun. 4 at 2:23 PM
0 · Reply
X600X
X600X Jun. 4 at 2:23 PM
$ATYR Gooooooo $ATYR
0 · Reply
Cheffinance
Cheffinance Jun. 4 at 1:42 PM
$ATYR I don't like this kind of decision about 8k. What they want to do now? This is very strange...something is cooking but I don't understand if it's something good or bad...
1 · Reply
DeexNutzz
DeexNutzz Jun. 4 at 2:09 AM
$ATYR The 180 day extension is in the bag the June 2nd deadline passed with no effect but I don’t much expect a big move from the extension. The fireside chat and the new phase 3 Ind may post a moderate bump but above $1 on that alone I bot site about. Good phase 2 EFZOFIT news will bring a big move and the rub up to that announcement will ensure our compliance. That will also be a good time for an offering to raise money but keep us above $1 per share. Keep in mind EFZOFITOMOD is worth 2 billion if it goes to markwt and their product currently in phase 2 is worth 5 billion if it goes to market! YUM! This is a long term play and I am using crypto play leverage money for it and with crypto tanking and going into crypto winter it is better to keep it here until thing thaw and I may make money to boot!
0 · Reply
X600X
X600X Jun. 3 at 10:57 PM
$ATYR $RDW $SLS $SPIR Dear Short's the Snake just waiting for your Action , don't Short and just go Home.
0 · Reply
SpartanTrader117
SpartanTrader117 Jun. 3 at 10:46 PM
$ATYR I got a buy order in at .49 hoping I can get that filled
0 · Reply
Cheffinance
Cheffinance Jun. 3 at 9:37 PM
$ATYR 8k tomorrow could be the best for the price. The company has got 4 days to publish after the date expired of 2 june. So it could be 4,5 or 8 june.
2 · Reply
Kadote
Kadote Jun. 3 at 9:33 PM
$ATYR The Jefferies fireside chat tomorrow is real (3:45pm ET), and the IND submission for the new Phase 3 sarcoidosis study is expected this month — those are legitimate near-term catalysts. But an 8-K tomorrow is speculation, nothing has been announced. A squeeze to $1+ based on a conference presentation would be unusual for a clinical-stage biotech with no data readout scheduled. The real catalyst is EFZO-CONNECT Phase 2 readout in Q4 2026 — that's what moves the needle long-term. Trade the facts, not the hype.
0 · Reply
Cheffinance
Cheffinance Jun. 3 at 8:23 PM
$ATYR ok we are arrived at the last step. They need to filed 8k tomorrow pre market, with the conference during the day the squeeze will be massive, taking the price above 1usd and probably more up after the conference. If I'm not wrong, the next two days will be epic.
0 · Reply
Cheffinance
Cheffinance Jun. 3 at 6:13 PM
$ATYR oh oh...someone is covering/buying? Tomorrow will be the congress, they clearly need to arrive with the compliance so...ready to fly my friends!!!
0 · Reply
SpartanTrader117
SpartanTrader117 Jun. 3 at 5:03 PM
0 · Reply
FeliciaMath
FeliciaMath Jun. 3 at 3:13 PM
sold $ATYR at .51 lost $145/7%
0 · Reply
Cheffinance
Cheffinance Jun. 2 at 8:57 PM
$ATYR the silence before the storm...i love it
0 · Reply
DeexNutzz
DeexNutzz Jun. 2 at 8:02 PM
$ATYR I bought a little more at a good price!
0 · Reply
Cheffinance
Cheffinance Jun. 2 at 6:58 PM
$ATYR are you sure? So look how they cover before the end, waiting the 8k after hour...
1 · Reply
jamersonmoody
jamersonmoody Jun. 2 at 5:52 PM
$ATYR shorted again lol
0 · Reply
SpartanTrader117
SpartanTrader117 Jun. 2 at 3:03 PM
0 · Reply